Characteristics | Andersen-Gill model without IPW | Andersen-Gill model with IPW | ||
Adjusted HR (95% CI) | P value | Adjusted HR (95% CI) | P value | |
Female sex | 1.36 (1.10 to 1.68) | 0.0051 | 1.13 (0.85 to 1.50) | 0.4122 |
Age per 10 years | 1.21 (1.13 to 1.31) | <0.0001 | 1.25 (1.14 to 1.37) | <0.0001 |
Glucocorticoids, 5–10 vs 0 mg/day | 1.42 (1.19 to 1.69) | <0.0001 | 1.47 (1.17 to 1.85) | 0.0008 |
Glucocorticoids, >10 vs 0 mg/day | 3.57 (2.36 to 5.39) | <0.0001 | 4.42 (2.50 to 7.83) | |
csDMARD treatment | Reference | Reference | ||
Monoclonal anti-TNF antibodies | 1.73 (1.34 to 2.24) | <0.0001 | 1.63 (1.17 to 2.28) | 0.0042 |
Soluble TNF receptor fusion protein | 1.45 (1.09 to 1.94) | 0.0121 | 1.28 (0.90 to 1.81) | 0.1687 |
T cell costimulation modulator | 1.25 (0.85 to 1.85) | 0.2608 | 1.45 (0.86 to 2.46) | 0.1652 |
B cell targeted therapy | 1.62 (1.21 to 2.18) | 0.0013 | 1.57 (1.03 to 2.40) | 0.0355 |
IL-6 inhibitors | 1.41 (1.06 to 1.89) | 0.0200 | 1.44 (0.99 to 2.11) | 0.0578 |
JAK inhibitors | 3.23 (2.32 to 4.48) | <0.0001 | 3.66 (2.38 to 5.63) | <0.0001 |
P values <0.05 are shown in bold.
Weights were estimated using the variables age, sex, disease duration, DAS28, FFbH, previous treatment with bDMARDs/tsDMARDs and osteoporosis.
bDMARDs, biologic DMARDs; csDMARDs, conventional synthetic DMARDs; DAS28, Disease Activity Score of 28 joints using the erythrocyte sedimentation rate; DMARDs, disease-modifying antirheumatic drugs; FFbH, Hannover Functional Status Questionnaire; IL-6, interleukin 6; IPW, inverse probability weights; JAK, Janus kinase; TNF, tumour necrosis factor; tsDMARDs, targeted synthetic DMARDs.